259 related articles for article (PubMed ID: 30985497)
1. The tumor microenvironment in renal cell cancer.
Mier JW
Curr Opin Oncol; 2019 May; 31(3):194-199. PubMed ID: 30985497
[TBL] [Abstract][Full Text] [Related]
2. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
[TBL] [Abstract][Full Text] [Related]
3. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
Hah YS; Koo KC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
[TBL] [Abstract][Full Text] [Related]
4. Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells.
Zhang XF; Weng DS; Pan K; Zhou ZQ; Pan QZ; Zhao JJ; Tang Y; Jiang SS; Chen CL; Li YQ; Zhang HX; Chang AE; Wicha MS; Zeng YX; Li Q; Xia JC
Mol Carcinog; 2017 Nov; 56(11):2499-2511. PubMed ID: 28621442
[TBL] [Abstract][Full Text] [Related]
5. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
6. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.
Jian Y; Yang K; Sun X; Zhao J; Huang K; Aldanakh A; Xu Z; Wu H; Xu Q; Zhang L; Xu C; Yang D; Wang S
Front Immunol; 2021; 12():639636. PubMed ID: 33767709
[TBL] [Abstract][Full Text] [Related]
7. Current Immunotherapies for Renal Cell Carcinoma.
Al-Marrawi MY; Holder SL
Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
[TBL] [Abstract][Full Text] [Related]
8. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in kidney cancer: the past, present, and future.
Hammers H
Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
[TBL] [Abstract][Full Text] [Related]
10. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
11. Renal cell cancer: is immunotherapy dead?
Wagstaff J
Ann Oncol; 2007 Jul; 18 Suppl 9():ix94-7. PubMed ID: 17631604
[No Abstract] [Full Text] [Related]
12. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
Kawashima A; Uemura M; Nonomura N
Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
[TBL] [Abstract][Full Text] [Related]
13. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.
Zhang Y; Narayanan SP; Mannan R; Raskind G; Wang X; Vats P; Su F; Hosseini N; Cao X; Kumar-Sinha C; Ellison SJ; Giordano TJ; Morgan TM; Pitchiaya S; Alva A; Mehra R; Cieslik M; Dhanasekaran SM; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099557
[TBL] [Abstract][Full Text] [Related]
14. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
[TBL] [Abstract][Full Text] [Related]
15. The immunology of renal cell carcinoma.
Díaz-Montero CM; Rini BI; Finke JH
Nat Rev Nephrol; 2020 Dec; 16(12):721-735. PubMed ID: 32733094
[TBL] [Abstract][Full Text] [Related]
16. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.
Raimondi A; Randon G; Sepe P; Claps M; Verzoni E; de Braud F; Procopio G
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480348
[TBL] [Abstract][Full Text] [Related]
17. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
Tadano H; Tsukahara T; Mizushima E; Akamatsu A; Watanabe K; Nojima I; Kubo T; Kanaseki T; Hirohashi Y; Sato N; Torigoe T
Br J Cancer; 2020 Oct; 123(9):1387-1394. PubMed ID: 32753678
[TBL] [Abstract][Full Text] [Related]
18. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for renal cell cancer.
Yang JC; Childs R
J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
[TBL] [Abstract][Full Text] [Related]
20. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Perego G; Barzaghi P; Vavassori I; Petrelli F
Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]